Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI

The goal of this clinical trial is to learn if reducing the duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (short treatment regimen, stopping aspirin at day 7) is as safe and efficient as the standard DAPT duration (standard treatment regimen) in elderly patients ≥ 65 years. The main questions it aims to answer are: Does the reduction of the duration of DAPT reduces rates of bleeding without increasing the risk of cardiovascular events? Researchers will compare a short treatment by DAPT (7 days, followed by single antiplatelet therapy) to a standard treatment duration by DAPT (3 to 12 months) after successful percutaneous coronary intervention with ≥ 1 drug-eluting stent. Participants will: * Take aspirin for 7 days in one group or 3 to 12 months in another group * Be contacted by phone at 7 days, 14 days, 21 days, 30 days, 3 months, 6 months and 12 months after hospital discharge * Keep a diary of any bleeding or cardiovascular events occurring during the study period

NCT Number	NCT07164859
Lead Sponsor	Vincent ROULE
Conditions	Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy, Elderly (People Aged 65 or More)
Enrollment	1,700 participants
Start Date	2025-10
Primary Completion	2029-10 (estimated)
Study Completion	2029-10 (estimated)
Updated on ClinicalTrials.gov	2025-10-01